Courage Capital Management’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-10,000
Closed -$829K 31
2022
Q1
$829K Hold
10,000
0.79% 25
2021
Q4
$751K Hold
10,000
0.5% 30
2021
Q3
$1.16M Hold
10,000
0.62% 26
2021
Q2
$2.22M Hold
10,000
1.33% 19
2021
Q1
$1.32M Hold
10,000
0.97% 23
2020
Q4
$1.73M Hold
10,000
1.72% 13
2020
Q3
$1.11M Hold
10,000
1.24% 21
2020
Q2
$593K Hold
10,000
1.09% 21
2020
Q1
$673K Hold
10,000
1.52% 22
2019
Q4
$843K Hold
10,000
2.55% 7
2019
Q3
$748K Sell
10,000
-10,000
-50% -$800K 1.2% 10
2019
Q2
$1.26M Hold
20,000
2.15% 9
2019
Q1
$963K Sell
20,000
-20,000
-50% -$963K 0.83% 9
2018
Q4
$1.34M Sell
40,000
-80,000
-67% -$2.93M 1.04% 11
2018
Q3
$6.29M Sell
120,000
-155,000
-56% -$6.17M 3.41% 6
2018
Q2
$8.61M Hold
275,000
6.43% 4
2018
Q1
$6M Buy
275,000
+175,000
+175% +$3.76M 4.57% 5
2017
Q4
$2.02M Buy
100,000
+25,000
+33% +$481K 1.44% 7
2017
Q3
$1.49M Sell
75,000
-75,000
-50% -$1.47M 1% 10
2017
Q2
$2.6M Sell
150,000
-326,717
-69% -$4.22M 1.33% 9
2017
Q1
$3.86M Sell
476,717
-23,283
-5% -$168K 3.18% 7
2016
Q4
$3.92M Hold
500,000
2.43% 8
2016
Q3
$4.27M Buy
+500,000
New +$4.56M 1.65% 4

Other funds holding NVCR

Courage Capital Management's NVCR Position: Q2 2022 in Review

Courage Capital Management sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 10,000 shares — an estimated $829K sold.

Courage Capital Management first reported a position in NVCR in Q3 2016 and held it in 23 quarters. The position peaked at $8.61M in Q2 2018. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

  • Courage Capital Management reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
  • Courage Capital Management sold 10,000 NovoCure shares in Q2 2022, an estimated $829K.
  • Courage Capital Management first reported a position in NovoCure in Q3 2016 and held it in 23 quarters.
  • Courage Capital Management's NovoCure position peaked at $8.61M in Q2 2018.
  • 316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Courage Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.